Yi Zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2929294/publications.pdf Version: 2024-02-01



YI THENC

#	Article	IF	CITATIONS
1	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	9
2	Estimation of piperacillin clearance with different glomerular filtration rate formulas in critically ill children. British Journal of Clinical Pharmacology, 2021, 87, 1275-1281.	1.1	2
3	Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. Journal of Clinical Pharmacology, 2021, 61, 677-687.	1.0	4
4	Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients. Therapeutic Drug Monitoring, 2021, 43, 131-135.	1.0	8
5	Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 196, 113923.	1.4	4
6	Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. European Journal of Clinical Pharmacology, 2021, 77, 1687-1695.	0.8	2
7	Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. Journal of Clinical Pharmacology, 2021, 61, 1366-1375.	1.0	О
8	Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory – immunonologic conditions. Fundamental and Clinical Pharmacology, 2020, 34, 270-278.	1.0	3
9	Population pharmacokinetics of meropenem in critically ill children with different renal functions. European Journal of Clinical Pharmacology, 2020, 76, 61-71.	0.8	30
10	Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
11	Maternal Betamethasone for Prevention of Respiratory Distress Syndrome in Neonates: Population Pharmacokinetic and Pharmacodynamic Approach. Clinical Pharmacology and Therapeutics, 2020, 108, 1026-1035.	2.3	16
12	HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 182, 113119.	1.4	19
13	Are β-lactam concentrations adequate in severe sepsis and septic shock in children?. Therapie, 2020, 75, 633-640.	0.6	5
14	Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically III Children with Normal and Augmented Renal Clearance. Clinical Pharmacokinetics, 2019, 58, 223-233.	1.6	42
15	Simultaneous quantification of levofloxacin, pefloxacin, ciprofloxacin and moxifloxacin in microvolumes of human plasma using highâ€performance liquid chromatography with ultraviolet detection. Biomedical Chromatography, 2019, 33, e4506.	0.8	21
16	Simulations of Valproate Doses Based on an External Evaluation of Pediatric Population Pharmacokinetic Models. Journal of Clinical Pharmacology, 2019, 59, 406-417.	1.0	6
17	Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1020-1024.	1.3	1
18	Suboptimal cotrimoxazole prophylactic concentrations in HIVâ€infected children according to the WHO guidelines. British Journal of Clinical Pharmacology, 2017, 83, 2729-2740.	1.1	4

YI ZHENG

#	Article	IF	CITATIONS
19	A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. Clinical Pharmacokinetics, 2017, 56, 537-550.	1.6	47
20	Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clinical Biochemistry, 2015, 48, 406-411.	0.8	40